Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
-
- Helena Ågerstam
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Christine Karlsson
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Nils Hansen
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Carl Sandén
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Maria Askmyr
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Sofia von Palffy
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Carl Högberg
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Marianne Rissler
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Mark Wunderlich
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229;
-
- Gunnar Juliusson
- Department of Hematology and Vascular Disorders, Skåne University Hospital, 22185 Lund, Sweden;
-
- Johan Richter
- Department of Hematology and Vascular Disorders, Skåne University Hospital, 22185 Lund, Sweden;
-
- Kjell Sjöström
- Innovagen AB, 22370 Lund, Sweden;
-
- Ravi Bhatia
- Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294
-
- James C. Mulloy
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229;
-
- Marcus Järås
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
-
- Thoas Fioretos
- Department of Clinical Genetics, Lund University, 22184 Lund, Sweden;
書誌事項
- 公開日
- 2015-08-10
- DOI
-
- 10.1073/pnas.1422749112
- 公開者
- National Academy of Sciences
この論文をさがす
説明
<jats:title>Significance</jats:title> <jats:p>Acute myeloid leukemia (AML) is a hematologic malignancy with poor survival. Current treatment with chemotherapy does not target the leukemic cells specifically and is associated with severe side effects. Here we demonstrate that antibodies directed at the cell surface molecule IL-1 receptor accessory protein (IL1RAP), expressed on immature AML cells, show strong antileukemic effects in mice transplanted with human AML cells and that the mechanism behind the cell killing is through recruitment of effector cells. Using antibodies against IL1RAP also capable of blocking IL-1 signaling, we show that the proliferation of human AML cells can be inhibited, providing a second mode of action of IL1RAP antibodies. These results provide critical evidence in support of a rapid clinical development of an antibody-based anti-IL1RAP therapy in AML.</jats:p>
収録刊行物
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 112 (34), 10786-10791, 2015-08-10
National Academy of Sciences
